Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.75 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.65 |
| ▸ | MLKL | Q8NB16 | 2/20 | 0.65 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.65 |
| ▸ | AURKA | O14965 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4809268 | 0.94 | KDR (0.85) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL4812504 | 0.90 | KDR (0.75) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL4811371 | 0.88 | KDR (0.72) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL4811907 | 0.88 | KDR (0.75) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL4817087 | 0.85 | KDR (1.00) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL4814390 | 0.84 | KDR (0.86) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL19913010 | 0.84 | KDR (0.90) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL4814501 | 0.83 | KDR (0.85) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL17979953 | 0.83 | KDR (0.77) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL17261032 | 0.83 | KDR (0.70) | KDRRIPK1MLKLRIPK3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459455-B2 | Pyrimidine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | claimed |
| US-20050085637-A1 | Antiproliferative agents; angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-04-21 | — | — | US | claimed |
| EP-1472233-A1 | PYRIMIDINE COMPOUNDS | SmithKline Beecham Corporation (US) | 2004-11-03 | — | — | EP | claimed |
| WO-2003066601-A1 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| US-7459455-B2 | Pyrimidine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459455-B2 | Pyrimidine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459455-B2 | Pyrimidine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050085637-A1 | Antiproliferative agents; angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-04-21 | — | — | US | disclosed |
| EP-1472233-A1 | PYRIMIDINE COMPOUNDS | SmithKline Beecham Corporation (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066601-A1 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085637-A1 | Antiproliferative agents; angiogenesis inhibitors | TIE1, TEK, KDR | KDR 3/4885RIPK1 2377/4885MLKL 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.